Cenk Gökalp
banner
cenkgokalp.bsky.social
Cenk Gökalp
@cenkgokalp.bsky.social
Nephrologist • Photography Enthusiast
Instagram: @dr.cenkgokalp
Reposted by Cenk Gökalp
Executive summary of the #KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy ( #IgAN) and Immunoglobulin A Vasculitis ( #IgAV)

doi.org/10.1016/j.kint.2025.04.003

#OpenAccess #MedSky #NephSky #glomerulardisease @imperialcollegeldn.bsky.social
September 23, 2025 at 3:14 PM
Reposted by Cenk Gökalp
Now open access in @NDTsocial

Anti-GBM disease - Treatment Standard

🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment

▶️ academic.oup.com/ndt/article/...
September 18, 2025 at 8:15 PM
Reposted by Cenk Gökalp
Core Curriculum by Biff F. Palmer and Deborah J. Clegg:

Mixed Acid-Base Disturbances: Core Curriculum 2025

bit.ly/Palmer25CC (FREE)
August 13, 2025 at 4:03 PM
Reposted by Cenk Gökalp
Now open access in @ndt-era.bsky.social

What do RCTs teach us about the pathophysiology of human IgAN?

🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever.

▶️ academic.oup.com/ndt/article/...
August 13, 2025 at 8:16 AM
Reposted by Cenk Gökalp
Diagnosis and Management of Osteoporosis in Advanced Kidney Disease: A Review ca. 2022 from @ajkd.bsky.social
#Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/34419519/
August 10, 2025 at 10:25 PM
Reposted by Cenk Gökalp
Join GlomCon this Sunday

Evaluation of Complement-Mediated Kidney Disease by Dr. Abdallah Geara

ID: 875 5077 1266
Passcode 202122

sign up 👉 bit.ly/signup-glomcon

#GlomCon
June 25, 2025 at 7:02 PM
Reposted by Cenk Gökalp
Sibeprenlimab Halves uPCR in IgA Nephropathy (IgAN) Trial from @medscape.com
#ERA25 🇦🇹 #Nephpearls #NephSky

👉 www.medscape.com/viewarticle/...
June 8, 2025 at 4:32 AM
Reposted by Cenk Gökalp
The Pathology Lesion Patterns of Podocytopathies: How and why?
#ERA25 🇦🇹 #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/35281116/
June 6, 2025 at 11:57 PM
Reposted by Cenk Gökalp
Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes:

a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)

doi.org/10.1093/ckj/...
Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Associatio...
ABSTRACT. Chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) represents a major public health issue; it develops in about 30%–40% of pa
doi.org
May 22, 2025 at 10:24 AM
Reposted by Cenk Gökalp
Clinical management of peripheral arterial disease in chronic kidney disease—a comprehensive review from the European Renal Association CKD-MBD Working Group

doi.org/10.1093/ckj/...
Clinical management of peripheral arterial disease in chronic kidney disease—a comprehensive review from the European Renal Association CKD-MBD Working Group
ABSTRACT. Peripheral artery disease (PAD) is a common and serious complication in people with chronic kidney disease (CKD) and end-stage kidney disease, oc
doi.org
May 21, 2025 at 1:47 PM
Reposted by Cenk Gökalp
Join GlomCon and IgAN Foundation this Sunday

IgA Nephropathy: A Clinical Update Plus the Patient Perspective by Dr. Richard Lafayette

ID: 875 5077 1266
Passcode 202122

sign up 👉 bit.ly/signup-glomcon

#GlomCon
May 14, 2025 at 5:33 PM
Reposted by Cenk Gökalp
Etiology of AKI in cirrhosis
#Nephpearls #RPA2025 🎰 #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/38070000/
April 6, 2025 at 6:02 PM
Reposted by Cenk Gökalp
Therapeutics to slow the progression of CKD and nephron loss in IgA Nephropathy (IgAN)
#Nephpearls #RPA2025 🎰 #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/39894081/
April 6, 2025 at 4:33 PM
Reposted by Cenk Gökalp
March 24, 2025 at 5:28 AM
Reposted by Cenk Gökalp
Diagnostic Algorithm for Evaluating Individuals With Numerous Bilateral Renal Cysts to Guide the Differentiation of ADPKD From Other Cystic Kidney Diseases ca. 2025 from @jama.com
#Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/40126492/
March 25, 2025 at 1:29 AM
Reposted by Cenk Gökalp
The potential benefits of SGLT2i have not "yet" been specifically explored in ADPKD, because the major trials of SGLT2i in nondiabetic CKD "excluded" those with ADPKD
#Nephpearls #NephJC #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/35373079/
March 26, 2025 at 1:45 AM
Reposted by Cenk Gökalp
Venous Thromboembolism Prevention in Nephrotic Syndrome: The Role of Aspirin, Vitamin K Antagonists, and Direct Oral Anticoagulants ca. 2025 from @kireports.bsky.social @saynanorouzi.bsky.social @kdjhaveri.bsky.social
#Nephpearls #NephSky

👉 www.kireports.org/article/S246...
April 3, 2025 at 12:38 PM